Kanavit

Phytomenadione, the active ingredient in Kanavit, is a Vitamin K presented as an injectable solution for intramuscular and intravenous use. It is employed to treat vitamin K deficiency, to prevent hemorrhage in newborns, and to reverse the anticoagulant effects of oral warfarin therapy.

GNH USA supplies Kanavit as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The product conforms to EU quality standards and is distributed under strict regulatory oversight. It is available for institutional procurement across multiple regions.

Kanavit is used in clinical situations that involve impaired vitamin K–dependent coagulation pathways.

- Vitamin K deficiency: restores normal clotting factor activity and reduces bleeding risk. - Newborn hemorrhage prevention: provides rapid vitamin K to newborns to prevent early‑life bleeding. - Warfarin therapy reversal: supplies vitamin K1 to counteract excessive anticoagulation and re‑establish hemostasis.

Adverse reactions to Kanavit may vary in frequency and severity.

Common Side Effects: - Injection site pain - Redness or swelling at the injection site - Headache - Nausea - Flushing - Transient fever

Serious or Rare Side Effects: - Anaphylactic or severe allergic reaction - Thrombosis or excessive clot formation - Hemolysis - Hypotension or shock - Acute renal failure - Severe skin necrosis

When using Kanavit, several safety considerations should be observed.

- Assess vitamin K status: evaluate baseline coagulation before administration. - Monitor coagulation parameters: check INR or PT after dosing. - Use caution in liver disease: impaired synthesis may affect response. - Avoid in known hypersensitivity: discontinue if allergic signs appear. - Adjust dose in neonates: follow pediatric guidelines. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Kanavit can interact with other medicines that affect coagulation or vitamin K metabolism.

Major Interactions (Avoid): - Concurrent use of other vitamin K antagonists (e.g., acenocoumarol, phenprocoumon). - Simultaneous administration of direct oral anticoagulants without appropriate reversal strategy.

Moderate Interactions (Monitor Closely): - Broad‑spectrum antibiotics (e.g., cephalosporins) that alter gut flora and vitamin K synthesis. - Lipid‑lowering agents (statins) that may affect vitamin K metabolism. - Oral contraceptives or hormone therapy influencing clotting balance. - Herbal supplements containing vitamin K (e.g., green leafy extracts).